Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
November 26, 2025 08:00 ET | Source: Precedence Research

Modified Antibody Market Poised USD 7.36 Billion by 2035, Driven by Personalized Medicine and Biopharmaceutical Research

Ottawa, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The global modified antibody market size is calculated at USD 3.38 billion in 2026 and is expected to reach around USD 7.36 billion by 2035, growing at a...
November 26, 2025 07:41 ET | Source: Research and Markets

Hyaluronic Acid Market Forecasts Report 2025-2030: Opportunities Driven by Demand for Non-surgical Cosmetic Procedures and Interest in Anti-aging Solutions

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Hyaluronic Acid Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Hyaluronic Acid Market is...
November 26, 2025 07:00 ET | Source: CG Oncology Inc.

CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...
November 26, 2025 06:57 ET | Source: Precedence Research

Teleneurology Market Size to Worth USD 20.30 Billion by 2034

Ottawa, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The global teleneurology market size is calculated at USD 6.75 billion in 2024, grows to USD 7.54 billion in 2025, and is projected to worth around USD...
November 25, 2025 08:10 ET | Source: Teva Pharmaceutical Industries Ltd

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA...
November 24, 2025 19:00 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG;...
November 24, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight

New York, USA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight The chronic refractory cough...
November 24, 2025 08:51 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Vancouver, Canada, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
November 24, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN is a highly aggressive, orphan...